Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
Affiliation
Paterson Laboratories and Radiotherapy Department, CHristie Hospital and Holt Radium Institute, Manchester M20 9BXIssue Date
1984-12
Metadata
Show full item recordAbstract
Serum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody 0C125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological types of carcinoma were antigen positive and there was a positive correlation between the frequency and level of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125 estimations following a prospective protocol. Variation in CA125 level reflected disease progression or regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week following chemotherapy and this effect predicted a good response to treatment. The natural half-life of CA125 in serum was estimated at approximately 4.8 days, sufficiently short to allow changes in tumour volume to be rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125 in the management of ovarian malignancy is discussed.Citation
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. 1984, 50 (6):765-9 Br J CancerJournal
British Journal of CancerPubMed ID
6208925Type
ArticleLanguage
enISSN
0007-0920Collections
Related articles
- Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
- Authors: Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW
- Issue date: 1985 Oct
- Evaluation of an immunoradiometric assay for the detection of an ovarian tumour marker, CA125, in serum.
- Authors: Shelley MD, Fish RG
- Issue date: 1986 May
- [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
- Authors: Iwasaka T, Ohkuma Y, Yoshimura T, Sugimori H
- Issue date: 1986 Jun
- The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.
- Authors: Fish RG, Shelley MD, Maughan T, Rocker I, Adams M
- Issue date: 1987 Jun
- Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
- Authors: McGuckin MA, Layton GT, Bailey MJ, Hurst T, Khoo SK, Ward BG
- Issue date: 1990 May